Prelude Therapeutics Incorporated filed its Form 10-Q for the quarterly period ended June 30, 2026, with the U.S. Securities and Exchange Commission, reporting its first period of recognized revenue alongside a narrowed net loss compared to the prior year.

Key Highlights

  • Revenue recognized: The company reported $5,704 thousand in revenue for Q2 2026, compared to $0 in Q2 2025, and $10,284 thousand for the six months ended June 30, 2026, compared to $0 in the same prior-year period.
  • Net loss narrowed: Net loss for Q2 2026 was $13,921 thousand ($0.14 per share), versus $31,231 thousand ($0.41 per share) in Q2 2025.
  • Six-month net loss: For the first half of 2026, net loss was $24,306 thousand ($0.27 per share), compared to $63,316 thousand ($0.83 per share) in the first half of 2025.
  • Equity offering completed: The company issued 16,611,014 shares of voting common stock and prefunded warrants in Q2 2026, net of issuance costs of $4,556.5 thousand, raising $85,443 thousand in proceeds.
  • Total assets grew: Total assets increased to $189,363 thousand at June 30, 2026, from $141,315 thousand at December 31, 2025, driven by growth in marketable securities from $67,958 thousand to $125,428 thousand.
  • Accumulated deficit: The accumulated deficit stood at $707,367 thousand as of June 30, 2026, up from $683,061 thousand at December 31, 2025.
  • Shares outstanding: As of August 6, 2026, the registrant had 79,803,485 shares of voting and non-voting common stock outstanding.

Prelude Therapeutics Reports First Revenue and Reduced Operating Losses in First Half of 2026

According to the filing, Prelude Therapeutics Incorporated (NASDAQ:PRLD) generated $10,284 thousand in revenue during the six months ended June 30, 2026, compared to no revenue in the same period of 2025. The company reported deferred revenue of $25,248 thousand as a current liability and zero deferred revenue as a non-current portion at June 30, 2026, down from a combined $35,532 thousand at December 31, 2025, reflecting the recognition of previously deferred amounts.

Total operating expenses fell significantly, according to the filing. Research and development expenses for the six months ended June 30, 2026 were $29,732 thousand, compared to $54,600 thousand in the prior-year period. General and administrative expenses were $10,183 thousand versus $12,200 thousand in the first half of 2025. These reductions contributed to a loss from operations of $29,631 thousand for the first half of 2026, compared to $66,800 thousand in the first half of 2025.

The company's balance sheet reflected the impact of a capital raise completed during Q2 2026. The filing disclosed that 16,611,014 shares of voting common stock and prefunded warrants were issued, netting $85,443 thousand after issuance costs of $4,556.5 thousand. Total stockholders' equity rose to $133,733 thousand at June 30, 2026, from $68,637 thousand at December 31, 2025. Cash and cash equivalents stood at $26,329 thousand, while marketable securities reached $125,428 thousand at quarter end. Net cash used in operating activities for the six months ended June 30, 2026 was $37,259 thousand, compared to $60,306 thousand in the same period of 2025.

What Was Disclosed

Prelude Therapeutics filed its unaudited quarterly report for the period ended June 30, 2026, disclosing its first recognized revenue, reduced operating expenses versus the prior year, a completed equity offering, and an accumulated deficit of $707,367 thousand.